GV101 in Healthy Obese Participants
Public ClinicalTrials.gov record NCT06979505. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Dose-ranging Double-blind, Placebo-controlled Phase 2 Trial of GV101 for Weight Loss in Healthy Obese Participants
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this trial is to evaluate the efficacy and safety of GV101 for weight loss over a range of doses in participants with obesity. The primary efficacy endpoint is the mean percent change in body weight from baseline at Week 16 in each treated group as compared with placebo.
Study identification
- NCT ID
- NCT06979505
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 131 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 29, 2025
- Primary completion
- Jan 27, 2026
- Completion
- Jan 27, 2026
- Last update posted
- Feb 3, 2026
2025 – 2026
United States locations
- U.S. sites
- 16
- U.S. states
- 13
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Lakeview Clinical Research, LLC | Guntersville | Alabama | 35976 | — |
| Arizona Clinical Trials | Tucson | Arizona | 85712 | — |
| Catalina Research Institute, LLC | Montclair | California | 91763 | — |
| Encompass Clinical Research | Spring Valley | California | 91978 | — |
| Louisville Metabolic and Atherosclerosis Research Center (L-MARC) | Louisville | Kentucky | 40213 | — |
| Tandem Clinical Research | Marrero | Louisiana | 70072 | — |
| Study Metrix Research | City of Saint Peters | Missouri | 63303 | — |
| Kansas City Research Institute | Kansas City | Missouri | 64131 | — |
| Mercury Street Medical | Butte | Montana | 59701 | — |
| Hassman Research Institute | Berlin | New Jersey | 08009 | — |
| Coastal Research Institute, LLC | Fayetteville | North Carolina | 28304 | — |
| Lillestol Research, LLC | Fargo | North Dakota | 58104 | — |
| Velocity Clinical Research - Cleveland | Cleveland | Ohio | 44122 | — |
| Velocity Clinical Research - Dallas | Dallas | Texas | 75230 | — |
| Advanced Research Institute - Ogden | Ogden | Utah | 84405 | — |
| Chrysalis Clinical Research | St. George | Utah | 84790 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06979505, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 3, 2026 · Synced Sep 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06979505 live on ClinicalTrials.gov.